Improving vacinne stability, potency, and delivery

American Pharmaceutical Review

Volumn 7, Issue 5, 2004, Pages 100-107

  Shi, Li ^a   Evans, Robert K ^a   Burke, Carl J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BACTERIAL VACCINE; BETA INTERFERON; CETRIMIDE; DNA VACCINE; DRUG PRESERVATIVE; EXCIPIENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE; INTERLEUKIN 12; ISCOM; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NAKED DNA; PEPTIDE DERIVATIVE; PLASMID DNA; POLIOMYELITIS VACCINE; POLYGLACTIN; POLYNUCLEOTIDE; POLYSACCHARIDE; QS 21; RECOMBINANT PROTEIN; UNINDEXED DRUG; VACCINE;

ARTICLE; CANCER; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MIXTURE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; GOOD MANUFACTURING PRACTICE; HEPATITIS B; HUMAN; NONHUMAN; VACCINATION;

EID: 7944239259     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Andrè, F.E., Vaccinology: past achievements, present roadblocks and future promises. Vaccine 21: 593-595 (2003).
2. Hilleman, M.R., Overview of the needs and realities for developing new and improved vaccines in the 21st Century. Intervirology 45: 199-211 (2002).
3. Maldonado, Y.A., Current controversies in vaccination. JAMA 288(24): 3155-3158 (2002) and references 1-3 in it.
4. Brandau, D.T., Jones, L.S., Wiefthoff, C.M., Rexroad, J., and Middaugh, C.R., Thermal Stability of Vaccines. J. Pharm. Sci, 92 (2): 218-231 (2003).
5. Sparkes, J.D. and Fenje, P., The effect of residual moisture in lyophilized smallpox vaccine on its stability at different temperatures, Bull. WHO 46: 729 (1972).
6. Thoelen, S., Clercq, N.D., Tornieporth, N., A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 19, 2400-2403 (2001) and references 2 and 5 in it.
7. Coates, T., Wilson, R., Patrick, G., Andre, F., Watson, V., Hepatitis B vaccines: an assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther. 23:392-403 (2001).
8. Alper C.A., The human immune response to hepatitis B surface antigen. Ex. Clin. Immunogenet. 12:171-181 (1995).
9. Zuckerman, J.N., Sabin, C., Craig, F.M., Williams, A., Zuckerman, A.J., Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomized double blind dose-response study. BMJ-Clinical Research Ed. 314 (7077): 329-333 (1997).
10. Zuckerman, J.N., Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response - third generation pre-S/S vaccines overcome non-response. J. Viral. Hepat. 5 (suppl 2): 13-15 (1998).
11. Papaevangelou, G., Current combined vaccines with hepatitis B. Vaccine (1998) 16:S69-S72.
12. Drain, P.K., Nelson, C.M., Lloyd, J.S., Single-dose versus multi-dose vaccine vials for immunization programs in developing countries. Bull. WHO 81(10): 726-731 (2003).
13. Cleland, J.L., Single-administration vaccines: controlled-release technology to mimic repeated immunizations. TIBTECH 17: 25-29 (1999).
14. Zhao, Z., and Leong, K.W., Controlled Delivery of Antigens and Adjuvants in Vaccine Development. J. Pharm. Sci. 85(12): 1261-1270 (1996).
15. Powell, M.F., Drug Delivery Issues in Vaccine Development. Pharm. Res. 13(12): 1777-1785 (1996).
16. Shi, L., Caulfield, M.J., Chern, R., Wilson, R.A., Sanyal, G., Volkin, D.B., Pharmaceutical and Immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci. 91(4): 101-1035 (2002).
17. Offit, P.A., Jew, R.K., Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 112(6): 1394-1401 (2003).
18. Hilleman, M.R., Vaccine perspectives from the vantage of hepatitis B. Vaccine Research 1(1): 1-15 (1992).
19. Sitrin, R.D., Wampler, D.E., Ellis, R.W., Survey of licensed hepatitis B vaccines and their production processes. In: Hepatitis B Vaccines in Clinical Practice. Ellis RW (eds), Marcel Dekker, Inc., New York, pp83-101 (1993).
20. Stephenne, J., Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 8 (suppl.): S69-S72 (1990).
21. Ellis, R. W. Technologies for the design, discovery, formulation and administration of vaccines. Vaccine 19, 2681-2687 (2001
22. Newman, M.J., Powell, M.F., Immunological and formulation design considerations for subunit vaccines in Vaccine Design: The subunit and adjuvant approach, edited by Powell and Newman, Plenum Press, New York, pp 1-42 (1995).
23. Baylor N.W., Egan, W., Richman, P., Aluminum salts in vaccines - US perspective. Vaccine 20: S18-S23 (2002).
24. Engers, H., Kieny, M.P., Malhotra, P., Pink, J.R., Third meeting on novel adjuvants currently in or close to clinical testing, World Health Organization, Fondation Mérieux, Annecy, France, 7-9 January 2002. Vaccine 21: 3503-3524 (2003).
25. Cox, J.C., Coulter, A.R., Adjuvants - a classification and review of their modes of action. Vaccine 15(3) 248-256 (1997).
26. Singh, M., O'Hagan, D.T., Recent Advances in Vaccine Adjuvants. Pharm. Res. 19(6): 715-728 (2002).
27. Donnelly, J.J., Ulmer, J.B., Liu, M.A., DNA vaccine. Life Science 60(3): 163-172(1997).
28. Donnelly, J.J., Berry, K., Ulmer, J.B., Technical and regulatory hurdles for DNA vaccines. Inter. J. Parasitol. 33:457-467 (2003).
29. Babiuk, L.A., Pontarollo, R., Babiuk, S., Loehr, B., van Drunen Little-van den Hurk. S., Induction of immune responses by DNA vaccines in large animals. Vaccine 21: 649-6583 (2003).
30. Kwissa, M., Kröger, A., Hauser, H., Reimann, J., Schirmbeck, R., Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. J. Mol. Med. 81: 91-101 (2003).
31. Lemieux, P. 2002. Technological advances to increase immunogenicity of DNA vaccines. Expert Rev. Vaccines 1:85-93.
32. Krieg, A.M., CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20:709-760 (2002).
33. Ulmer, J.B., DeWitt, C.M., Chastain, M., Friedman, A., Donnelly, J.J., McClements, W.L., Caulfield, M.J., Bohannon, K.E., Volkin, D.B., Evans, R.K., Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18:18-28, 2000.
34. Shiver J.W., Fu, M., Chen, L., Casimiro, D.R., Davies, M., Evans, R.K., Zhang, Z., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A., Long, R.S., Liang, X., Handt, L., Schleif W.A., Zhu, L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A., Collins, K.B., Heidecker, G.J., Perry, H.C., Joyce, J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B., Montefliori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda, M.J., Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C., and Emini, E.A. Replication-Incompentent Adenoviral Vaccine Vector Elicits Effective Anti-Immunodeficiency-virus Immunity. Nature 415, 331-335, 2002.
35. Haiching, M., Diamond, S.L., Nonviral gene therapy and its delivery systems. Cur. Pharm. Biotech. 2:1-17 (2001).
36. Tacket, C.O., Roy, M.J., Widera, G., Swain, W.F., Broome, S., Edelman, R., Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17:2826-2829 (1999).
37. Cui, Z., Mumper, R.J., Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit. Rev. Ther. Drug Car. Sys. 20:103-137 (2003).
38. Singh, M., Briones, M., Ott, G., O'Hagan, D., Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA 97: 811-816 (2000).
39. O'Hagan, D., Singh, M., Ugozzoli, M., Wild, C., Barnett, S., Minchao, C., Schaefer, M., Doe, B., Otten, G.R., Ulmer, J.B., Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 75:9037-9043 (2001).
40. Denis-Mize, K.S., Dupuis, M., MacKichan, M.L., Singh, M., Doe, B., O'Hagan, D., Ulmer J.B., Donnelly, J.J., McDonald, D.M., Ott, G., Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7:2105-2112 (2000).
41. Rabussay, D., Dev, N.B., Fewell, J., Smith, L.C., Widera, G., Zhang, L., Enhancement of therapeutic drug and DNA delivery into cells by electroporation. J. Phys. D: Appl. Phys. 36: 348-363 (2003).
42. Middaugh, C.R., Evans, R.K., Montgomery, D.L., Casimiro, D.R., Analysis of plasmid DNA from a pharmaceutical perspective. J. Pharm. Sci. 87: 130-146 (1998).
43. Evans, R.K., Xu, Z., Bohannon, K.E., Wang, B., Bruner M.W., Volkin, D.B., Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. J. Pharm. Sci. 89: 76-87 (2000).
44. Burke, C.J., Hsu, T.A., Volkin, D.B., Formulation, stability, and delivery of live attenuated vaccines for human use. Crit. Rev. Ther. Drug Carrier Syst. 16(1): 1-83 (1999).
45. Greiff, D., Rightsel, W.A., Stabilities of dried suspensions of influenza virus sealed in a vacuum or under different gases. Appl. Microbiol. 17(6): 830-5 (1969).
46. Bennet, P.S., Maigetter, R.Z., Olson, M.G., Provost, P.J., Scattergood, E.M., and Schofield, T.L., The effects of freeze-drying on the potency and stability of live varicella virus vaccine. Dev. Biol. Stand. 74: 215-221 (1991).
47. Clark, H.F., Burke, C.J., Volkin, D.B., Offit, P., Ward, R.L., Bresee, J.S., Dennehy, P., Gooch, W.M., Malacaman, E., Matson, D., Walter, E., Watson, B., Krah, D.L., Dallas, M.J., Schodel, F. Kaplan, K.M., Heaton, P., Safety, immunogenicity, and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Ped. Infect. Dis. J. 22: 914-920 (2003).
48. Jacobson, R.M., Swan, A., Adegbenro, A., Ludington, S.L., Wollan, P.C., Poland, G.A., Vaccine Research Group, Making vaccine more acceptable - methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine 19: 2418-2427 (2001 ).
49. Brazeau, G.A., Cooper, B., Svetic, K.A., Smith, C.L., Gupta, P., Current Perspective on pain upon injection of drugs. J. Pharm. Sci. 87(6): 667-677 (1998).
50. Nony, P., Girard, P., Chabaud, S., Hessel, L., Thebault, C., Boissel, J.P., Impact of osmolality on burning sensations during and immediately after intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults, Vaccine 19: 3645-3651 (2001).